AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05078268 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HRV biofeedback training and self-help CBT-I
Description: Participants will receive a booklet with content related to both self-help CBT-I and HRV biofeedback per week for 6 consecutive weeks. Participants are required to use around 1 hour to read through the content and perform the HRV biofeedback practice for around 20 minutes a day, 5-7 days a week and record their practice.
Study NCT05078268 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-help CBT-I only
Description: Participants will receive a booklet with content related to self-help CBT-I only per week for 6 consecutive weeks. Participants are required to use 30 to 40 minutes to read through the content.
Study NCT06413030 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 10 Meter Walk Test
Description: Gait Speed Test
Study NCT04945109 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mankai beverage
Description: Recommended background healthy diet with Mankai supplementation after main meal (300 ml)
Study NCT04945109 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water (control)
Description: Recommended background healthy diet with water supplementation after main meal (300 ml)
Study NCT04187170 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength physical training
Description: progressive high-load strength training over 6 months, consisting in repeated physical exercises to increase the muscular mass and force by altering concentric and eccentric muscle contractions against high resistance.
Study NCT05506319 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: The patients will be randomized for the initial suspension of norepinephrine (norepinephrine group).~Interruption means suspension for at least 24 hours.
Study NCT05506319 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vasopressin
Description: The patients will be randomized for the initial suspension of vasopressin (vasopressin group).~Interruption means suspension for at least 24 hours.
Study NCT04405180 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Oral placebo capsule at a dose of 20 mg administered three times per day, during the day.
Study NCT04405180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20mg sodium nitrite tid
Description: Oral, inorganic sodium nitrite capsule at a dose of 20 mg administered three times per day, during the day.
Study NCT04996654 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exergame
Description: According to the training concept, each participant is instructed to train 5x/week for 21 min per session resulting in a weekly exercise volume of 105 min. All training sessions are planned to take place at participant's homes using the exergame training system Dividat Senso (Dividat AG, Schindellegi, Switzerland; CE certification).
Study NCT04996654 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: An active control group will proceed with usual care as provided by the memory clinics where the patients are recruited.
Study NCT06250023 — intervention group
Intervention type: OTHER
Intervention: Early shift til oral antibiotic treatment for osteomyelitis
Description: To investigate whether early transition to oral AB treatment after one week of IV treatment is non-inferior to the current national guideline of continued IV AB treatment for two to four weeks followed by oral AB treatment for PVO.
Study NCT06145360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 MG
Description: the impact of incorporating Empagliflozin, an oral sodium-glucose co-transporter 2 (SGLT2) inhibitor, into the existing therapeutic regimen of Insulin+Metformin+DPP4 inhibitor (DPP4I) in poorly controlled type 2 diabetes mellitus (T2DM
Study NCT06145360 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin+Metformin+DPP4 inhibitor (DPP4I)
Description: Group B: usual care group but without Empagliflozin with adjustment of therapy as the standard of care
Study NCT05636930 — intervention group
Intervention type: OTHER
Intervention: Test the accuracy of the wearable device
Description: No intervention was done for the subjects
Study NCT05953896 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid gel
Description: For the Hyaluronic acid gel group: HA gel was injected 2-3mm apical to the coronal tip of the involved papillae and the needle was directed coronally with an angulation of 45° to the long axis of the tooth, and the bevel directed apically until papilla became blanched. The injection was given at each papilla at the following intervals baseline, one week and two weeks.
Study NCT05953896 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Multilayer L-PRF membranes
Description: For the multilayer L-PRF group: A single semilunar incision is made in the buccal vestibule, apical to the muco-gingival junction in the mid interproximal area of the papilla to be treated.Tunneling of the incisions has maintained the full height and thickness of the gingiva. Multilayer L-PRF membranes were prepared according to Pinto's protocol immediately prior to the surgery and placed in the tunnel then incision was closed with simple interrupted sutures.
Study NCT04824118 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Thromboelastometry
Description: Point of Care Test for clotting parameters (ClotPro device)
Study NCT04824118 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Clotting Studies
Description: Standard laboratory tests for clotting:~* International normalised ratio (INR)~* Prothrombin time (PT)~* adjusted partial thromboplastin time (aPTT)~* fibrinogen
Study NCT04824118 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Full Blood Count
Description: For platelet count
Study NCT04824118 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Quantitative hCG
Description: Serum human chorionic gonadotrophin
Study NCT04824118 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pregnancy Test
Description: Point of care urinary pregnancy test
Study NCT04759391 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Pelvic floor muscle training program planned under the supervision of a physiotherapist was applied and followed to the exercise group, using the digital application.
Study NCT04759391 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle recommendations
Description: Information was given within the scope of lifestyle recommendations (fluid intake, diet, constipation, weight control, smoking related to lower urinary system symptoms
Study NCT04759391 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lifestyle recommendations
Description: Information was given within the scope of lifestyle recommendations (fluid intake, diet, constipation, weight control, smoking related to lower urinary system symptoms
Study NCT04536181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: 12 weeks prednisolone treatment
Study NCT04536181 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 12 weeks simulated tablets
Study NCT04703712 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lens extraction combined with goniosynechialysis
Description: The patients enrolled underwent phacoemulsification combined with goniosynechialysis surgery.
Study NCT04703712 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trabeculectomy surgery
Description: The patients enrolled underwent trabeculectomy surgery
Study NCT05167955 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness based cognitive intervention based on the behavioural change techniques taxonomy
Description: An online mindfulness-based cognitive intervention is used as a proposed treatment intervention for erectile dysfunction among African- Caribbean men based in the United Kingdom.
Study NCT05167955 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mindfulness based cognitive intervention based on the behavioural change techniques taxonomy
Description: An online mindfulness-based cognitive intervention is used as a proposed treatment intervention for erectile dysfunction among African- Caribbean men based in the United Kingdom.
Study NCT06354387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectinib (Alecensa), Nivolumab (Opdivo)
Description: Alectinib (Alecensa) in Combination with Nivolumab (Opdivo)
Study NCT04622813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nefopam, ketoprofen, paracetamol
Description: Patients in this group will receive Nefopam and Ketoprofen in addition to the paracetamol intraoperatively prior to the anticipated end of the surgery
Study NCT04622813 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline infusion, ketoprofen, paracetamol
Description: Patients in this group will receive one placebo infusion (saline infusion) in addition to the ketoprofen and paracetamol intraoperatively prior to the anticipated end of the surgery
Study NCT05016843 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment condition: Internet-administered Unified protocol
Description: Treatment condition:~The cognitive, behavioral treatment Unified protocol is a transdiagnostic treatment for anxiety and depression. Participants are taught five techniques in order to find new and more helpful ways to react to hindering thoughts and feelings: mindfulness, cognitive flexibility, identify and reduce behavioral avoidance, increase willingness to experience physiological sensations and exposure. The intervention is delivered online through a secure platform. Modules consist of text and the participants can work with the material whenever they wish to. Participants gain access to a new treatment modul every week.
Study NCT05016843 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment condition: Internet-administered Affect phobia treatment
Description: The aim of psychodynamic Affect phobia treatment is for the patient to reach an intellectual and emotional understanding of his/hers problems. The goal of the treatment is for participants to decrease emotional avoidance and start to approach emotions and increase emotional awareness. Participants are taught this through linking their symptoms to their emotional avoidance, observe frequent and maladaptive patterns in relationships and see how these are linked to emotional avoidance. The intervention is delivered online through a secure platform. Modules consist of text and the participants can work with the material whenever they wish to. Participants gain access to a new treatment modul every week.
Study NCT05016843 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment condition: Waitlist control
Description: The waitlist condition is a control condition without any intervention.
Study NCT06504199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: No dose adjustment of Obinutuzumab is allowed.
Study NCT03171129 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adaptive Dynamic Inspiratory Nasal Apparatus
Description: Oxygen will be administered via ADINA
Study NCT03171129 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High flow Nasal Canula
Description: Oxygen will be administered via nasal canula
Study NCT05448651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UPB-101
Description: Subcutaneous injection
Study NCT05448651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneous injection
Study NCT05692427 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Cryopen - Cryotherapy
Description: Cryotherapy with N20
Study NCT05321264 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational nursing intervention
Description: Four weekly individualized intervention sessions, with a duration of 40 minutes.
Study NCT04710628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg will be administered to patients as 30-minute intravenous infusion (a window of -5 minutes and +10 minutes is permitted) every 3 weeks.
Study NCT04710628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib 10 mg
Description: Lenvatinib 20 mg (2 capsules of 10 mg) will be administered daily at the same time, with or without food. At the day 1 of each cycle, lenvatinib will be administered within 4 hours after finishing pembrolizumab (lenvatinib after pembrolizumab)
Study NCT04695444 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nasotracheal tube (Ring-Adair-Elwin)
Description: different materials for nasotracheal intubation conventional PVC tube
Study NCT04695444 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nasotracheal tube (Ring-Adair-Elwin)
Description: different materials for nasotracheal intubation conventional PVC tube with rubber suction catheter
Study NCT04695444 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nasotracheal tube (portex)
Description: different materials for nasotracheal intubation velvet soft PVC tube.
Study NCT04193982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saroglitazar
Description: Patient receives Saraglitazar 4mg once daily
Study NCT04193982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin E
Description: Patient receive Vitamin E 400mg twice daily after food for 6 months
Study NCT04193982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination drug
Description: Patient receives Vitamine E 400mg twice daily and Saraglitazar 4 mg once daily for 6 months
Study NCT04193982 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle Changes
Description: Patients receives dietary advise and does exercise in form of aerobic and targets 7 to 10 percent weight loss in 6 months
Study NCT06504199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Zanubrutinib was allowed to be titrated to 80 mg bid or 80 mg qd
Study NCT06504199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide was allowed to be titrated to 15 mg/day (induction phase) or 5 mg/day (maintenance phase).
Study NCT06022198 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchoalveolar Lavage
Description: Bronchoalveolar Lavage
Study NCT05104684 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: chest physical therapy
Description: The program will consist of postural drainage, diaphragmatic breathing exercises, coughing, huffing, percussion, shaking, and exercise training using an incentive spirometer in addition to routine medical treatment
Study NCT05104684 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: routine medical treatment
Description: medical treatment
Study NCT05104684 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: routine medical treatment
Description: medical treatment
Study NCT05320133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JWC containing quadruple therapy
Description: Subjects will receive the rabeprazole 10mg, moxycillin 1.0g, clarithromycin 500mg and Jinghua Weikang Capsule 240mg twice daily for 14 days.
Study NCT05320133 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bismuth-containing quadruple therapy
Description: Subjects will receive the rabeprazole 10mg, moxycillin 1.0g, clarithromycin 500mg and bismuth potassium citrate 220mg twice daily for 14 days.
Study NCT05016843 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment length: 8 weeks
Description: Participants will partake in their treatment condition for 8 weeks.
Study NCT05016843 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment length: 16 weeks
Description: Participants will partake in their treatment condition for 16 weeks.
Study NCT05016843 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Access to a moderated forum
Description: During their treatment, participants will have access to a discussion forum moderated by a clinician. Participants are encouraged to discuss questions and experiences related to their treatment condition.
Study NCT05016843 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No access to a moderated forum
Description: Participants will not have access to a moderated forum, hence their treatment is self-guided.
Study NCT05600582 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CodaLytic
Description: CodaLytic is a virotherapeutic product based on the wild-type influenza strain A/California/07/2009
Study NCT06508229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: adebrelimab, IV
Study NCT06508229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albumin paclitaxel
Description: albumin paclitaxel, iv
Study NCT06508229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nedaplatin
Description: Nedaplatin，IV
Study NCT05799794 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supervisor-led Implementation Coaching
Description: Implementation coaching, support, or facilitation includes the support provided to supervisors and their organizations for successfully delivering an evidence-based practice (EBP). Implementation support can include consultation, supervision, and coaching.
Study NCT05799794 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervisor-led Implementation Coaching
Description: Implementation coaching, support, or facilitation includes the support provided to supervisors and their organizations for successfully delivering an evidence-based practice (EBP). Implementation support can include consultation, supervision, and coaching.
Study NCT06485466 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: TACE plus camrelizumab and apatinib
Description: TACE plus camrelizumab and apatinib group:~Patients who were randomized to this group, TACE is performed via an injection into the hepatic artery of agents by puncturing the common femoral artery.Adriamycin(30 to 60 mg) and oxaliplatin (50-150mg) are considered as basic chemotherapy drugs in the process of transcatheter endovascular perfusion. The dose of lipiodol (5-20ml) and other embolic agent( blank microspheres/ PVA/gelatin sponge particles) were determined by diameter and blood supply type of HCC. Within 1 week after first TACE treatment, camrelizumab 200mg intravenously every 3 weeks and apatinib 250 mg orally once daily.
Study NCT06485466 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Camrelizumab and apatinib
Description: Camrelizumab and apatinib group:~Patients who were randomized to this group, camrelizumab 200mg intravenously every 3 weeks and apatinib 250 mg orally once daily.
Study NCT04891107 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Walking Program with a Music-based, Rhythm-modulating Wearable Sensor System
Description: Participants will walk using the music-based, rhythm-modulating wearable sensor system (foot sensors, mobile device with mobile app and headphones) for thirty (30) minutes at a time, 5 times a week for 4 weeks.
Study NCT06195189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunvozertinib
Description: Sunvozertinib 200mg Quaquedie (QD)
Study NCT06195189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Pemetrexed +platinum
Study NCT05246813 — intervention group
Intervention type: OTHER
Intervention: Blood and bone marrow cell collection
Description: Collection of blood and bone marrow
Study NCT05243303 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active taVNS
Description: A bipolar clip electrode is placed at the cymba conchae of the ear. Through this bipolar clip electrode, afferent nerve fibers within the auricular branch of the vagus nerve will be stimulated. Subjects self-administer the stimulation on a daily basis for 3 months.
Study NCT05243303 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham taVNS
Description: A bipolar clip electrode is placed at the cymba conchae of the ear. However, active stimulation of the afferent nerve fibers within the auricular branch of the vagus nerve will not occur, because the electrode wire is electrically interrupted. Subjects self-administer the sham taVNS on a daily basis for 3 months.
Study NCT04839445 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia + TAP block
Description: Post induction TAP block for intra and postoperative analgesia.
Study NCT04839445 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia + ESP block
Description: Pre induction ESP block for intra and postoperative analgesia.
Study NCT05392036 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: baseline physical therapy treatment along with shockwave therapy
Description: Group A, this group will receive conventional therapies along with shockwave therapy. Basic treatment includes icing (15-20 min) to control inflammation, rest, cessation of pain causing activity, anti-inflammatory (NSAIDs) and basic stretching and strengthening exercises. Shockwave therapy is a non-invasive therapeutic modality with convenience, effectiveness and safety. It is used to treat various musculoskeletal disorders without surgery. A session of 30-45 min will include icing 15 min and 5-10 min of shock wave therapy session will be commenced with strengthening and stretching exercises.